Clinical trial
Short Course of Pegylated GCSF (Neulasta®) as Immunomodulatory Therapy for Type 1 Diabetes
NCT00662519 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Short Course of Pegylated GCSF (Neulasta®) as Immunomodulatory Therapy for Type 1 Diabetes
- Lead sponsor
- University of Florida
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2008
- Completion date
- March 31, 2014
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 1 diabetes